Weekly cisplatin chemotherapy dosing versus triweekly chemotherapy with concurrent radiation for head and neck squamous cell carcinoma.

Background: Triweekly high-dose cisplatin (100 mg/m ² ) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m ² with alternative weekly 40 mg/m ² and weekly <40 mg/m ² cisplatin regimens.
Methods: From 2011 to 2016, 163 patients received concurrent cisplatin and intensity-modulated radiotherapy for locally advanced HNSCC. Primary endpoints were overall survival (OS) and progression-free survival.
Results: Cisplatin weekly <40 mg/m ² showed inferior OS outcomes when compared to weekly 40 mg/m ² (P = 0.084) and triweekly 100 mg/m ² (P = 0.04) regimens.
Conclusion: Our study displayed inferior outcomes with weekly cisplatin doses under 40 mg/m ² , suggesting the inferiority of low-dose weekly chemotherapy and the need for ongoing randomized trials to further explore 40 vs 100 mg/m ² chemotherapy regimens.
(© 2019 Wiley Periodicals, Inc.)